Table 1. Characteristics of the study women (N = 635).
| Age, median (IQR) | 41 (36–47) |
| Race/Ethnicity | |
| Black, non-Hispanic | 396 (62%) |
| White, non-Hispanic | 57 (9%) |
| Hispanic | 171 (27%) |
| Other | 11 (2%) |
| Recruitment cycle | |
| 1994–95 | 382 (60%) |
| 2001–02 | 253 (40%) |
| HCV statusa | |
| HCV antibody- | 448 (70%) |
| HCV antibody+/HCV RNA- | 43 (7%) |
| HCV antibody+/HCV RNA+ | 144 (23%) |
| Current CD4+ T-cell count (cells/µL)b | |
| <200 | 81 (13%) |
| 200–500 | 285 (45%) |
| >500 | 265 (42%) |
| Nadir CD4+ T-cell count (cells/µL) | |
| <200 | 260 (41%) |
| 200–500 | 297 (47%) |
| >500 | 78 (12%) |
| HIV subgroupc | |
| Untreated | 122 (19%) |
| Receipt of HAART and aviremic | 218 (34%) |
| Receipt of HAART and viremic | 295 (47%) |
IQR, interquartile range; HAART, highly active antiretroviral therapy.
a
HCV status was determined at enrollment. Follow-up HCV RNA testing was conducted on all women who were HCVAb+ at enrollment and HCV RNA status was 100% concordant between enrollment and follow-up testing (see Laboratory Methods).
b
Four women had missing CD4+ data at their CMV testing visit.
c
Untreated: no receipt of HAART; Treated and aviremic: undetectable HIV RNA for ≥50% of study visits following first reported receipt of HAART; Treated and viremic: HIV RNA levels above the lower level of detection for >50% of study visits following first reported receipt of HAART.